Cases
MEDNAX, Inc. (NYSE: MD)
Securities Class Action
Overview
Overview
- Date:
- 7/11/2018
- Company Name:
- MEDNAZ, Inc.
- Stock Symbol:
- MD
- Status:
- Closed/Complete
NEW YORK, July 11, 2018 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of Florida on behalf of all persons or entities who purchased or otherwise acquired MEDNAX, Inc. (NYSE: MD) securities between February 2, 2016 and July 27, 2017 (the “Class Period”). Investors have until September 10, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that, on July 28, 2017, Mednax announced, during its second quarter earnings call with investors and analysts, that the Company failed to complete any acquisitions of anesthesiologist practices during the quarter. Significantly, the Company also disclosed that any future anesthesiologist acquisitions were unlikely, which Mednax attributed to the “challenging” payor mix combined with “continued . . . growth in compensation expense for nurse anesthetists.” On this news, the price of Mednax stock declined from $56.49 per share on July 27, 2017, to close at $47.73 per share on July 28, 2017, a drop of 15.5%.
If you purchased Mednax securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights orinterests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The complaint alleges that, on July 28, 2017, Mednax announced, during its second quarter earnings call with investors and analysts, that the Company failed to complete any acquisitions of anesthesiologist practices during the quarter. Significantly, the Company also disclosed that any future anesthesiologist acquisitions were unlikely, which Mednax attributed to the “challenging” payor mix combined with “continued . . . growth in compensation expense for nurse anesthetists.” On this news, the price of Mednax stock declined from $56.49 per share on July 27, 2017, to close at $47.73 per share on July 28, 2017, a drop of 15.5%.
If you purchased Mednax securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights orinterests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.